Thymosin Alpha 1 and Interferon Alpha Combinations for Advanced Melanoma

Malignant melanoma is an aggressive form of skin cancer with high metastatic potential, meaning it can spread rapidly throughout the body. Standard treatments often include chemotherapy like dacarbazine (DTIC), but outcomes for advanced stages remain challenging. Immunotherapies, such as interferon alpha (aIFN), have shown some promise by stimulating the immune system. However, there's a need for more effective combination strategies to improve patient survival and response rates. This Phase II study aimed to evaluate the safety and efficacy of adding the immunomodulatory peptide, thymosin alpha 1, to dacarbazine, with or without interferon alpha, for patients with advanced-stage metastatic malignant melanoma.

This clinical trial registration describes the study design and objectives for evaluating combination therapies in advanced melanoma, but does not provide the actual results regarding tumor response, overall survival, or progression-free survival. The study was designed to test if the combination therapies could achieve a tumor response rate (P1) of >= 0.15 compared to a null hypothesis (P0) of <= 0.05, with a statistical significance level (alpha) of 5% and a statistical power (beta) of 95% for within-group analysis. The primary outcome was to be assessed by RECIST criteria, which standardize how solid tumors are measured and categorized as responding, stable, or progressing. The study aimed to determine if adding Thymosin alpha 1 to dacarbazine, with or without interferon alpha, could significantly improve tumor response rates in patients with stage IV malignant melanoma.